logo
CareTrust REIT Inc (CTRE) Q1 2025 Earnings Call Highlights: Record Growth and Strategic UK Expansion

CareTrust REIT Inc (CTRE) Q1 2025 Earnings Call Highlights: Record Growth and Strategic UK Expansion

Yahoo03-05-2025
Normalized FFO: Increased 67.4% to $77.8 million.
Normalized FAD: Increased 66% to $80.8 million.
Normalized FFO per Share: Increased $0.07 or 20% to $0.42 per share.
Normalized FAD per Share: Increased $0.06 or 16.2% to $0.43 per share.
Investment Total: Year-to-date investments totaled approximately $82 million at a yield of approximately 10%.
Cash Rental Revenues: Projected to be approximately $284 million for the year.
Interest Income: Approximately $90 million, with $76 million from the loan portfolio and $14 million from cash invested in money market funds.
Interest Expense: Approximately $24.3 million, including $4 million of amortization of deferred financing fees.
G&A Expense: Approximately $33 million to $37 million, including $11.7 million of deferred stock costs.
Leverage: Net debt to normalized EBITDA ratio of 0.5 times; expected to be below 2.5 times post-UK transaction.
Fixed Charge Coverage Ratio: 15.2 times.
Warning! GuruFocus has detected 6 Warning Signs with CTRE.
Release Date: May 02, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
CareTrust REIT Inc (NYSE:CTRE) announced the strategic acquisition of Care REIT, marking its entry into the UK market and the largest deal in its history.
The acquisition diversifies CTRE's business in terms of operator concentration, geography, payer sources, and asset classes.
CTRE completed three new investments totaling over $47 million at a yield of approximately 10% during the first quarter.
Normalized FFO increased 67.4% over the prior year quarter to $77.8 million, and normalized FAD increased by 66% to $80.8 million.
CTRE's liquidity remains strong with a net debt to normalized EBITDA ratio of 0.5 times and a fixed charge coverage ratio of 15.2 times.
The acquisition of Care REIT involves assuming existing debt of approximately $259 million, which CTRE plans to refinance.
There is uncertainty regarding potential Medicaid cuts, which could impact CTRE's portfolio.
The UK acquisition pipeline is still developing, and it may take time to mature to the level of the US pipeline.
Interest expense increased due to the line draw for the escrow account related to the UK transaction.
CTRE's guidance assumes no additional investments or further debt or equity issuances this year, which could limit growth opportunities.
Q: Can you comment on the potential impacts of policy and provider taxes on your portfolio? A: David Sedgwick, President and CEO, stated that there is no change in their outlook on potential Medicaid cuts. They are monitoring the process, and there is bipartisan support for Medicaid, especially for seniors in nursing homes.
Q: What conditions lead you to choose debt investments over property acquisitions? A: David Sedgwick explained that acquisitions are prioritized, but debt investments are considered strategic if they can build relationships with key operators, potentially leading to future acquisitions.
Q: Are there any changes to the earnings or FAD accretion from the Care REIT transaction? A: David Sedgwick mentioned that they will provide detailed answers regarding the transaction's financial impact once the deal is officially announced.
Q: What is the expected investment pipeline volume for the UK market, and what yields are you seeing? A: David Sedgwick noted that the UK pipeline will take time to mature. They are currently looking at various deals with cap rates ranging from 7% to 9%, depending on the specifics.
Q: How are the properties performing relative to initial underwriting, and what is the outlook for PAC? A: David Sedgwick stated that they have no updates on PAC beyond the data and coverage ratios provided, and they are awaiting further disclosures.
Q: Does the UK acquisition put you on the map for new relationships, and will you start lending there? A: David Sedgwick confirmed that the acquisition has generated significant interest from operators in the UK, but they are not currently looking to lend in that market.
Q: How is the US skilled nursing facility (SNF) market changing, and is there less capital available? A: James Callister, Chief Investment Officer, stated that the market remains unchanged with consistent deal flow and competitive landscape, with no significant shifts in capital availability.
Q: What is the status of the term loan related to the UK acquisition, and what are the expected costs? A: William Wagner, CFO, explained that the term loan will be an amendment to their existing credit facility, with pricing just inside their revolver, and it will not be in pounds.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron
Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron

Yahoo

time3 minutes ago

  • Yahoo

Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) announced positive results from its Phase 3 ATTAIN-1 trial of Orforglipron, which is an oral drug for overweight adults without diabetes. The trial, which lasted 72 weeks and included 3,127 participants, showed significant weight loss compared to the placebo. The highest dose administered during the trial was 36 mg daily, which led to an average weight loss of 12.4%. Over half of the participants on this dose lost at least 10% of their body weight. Moreover, the drug also improved cardiovascular risk markers like cholesterol and blood pressure. Management noted that the safety profile of Orforglipron matched expectations for its class of drugs, and discontinuation due to side effects was low. The company plans to submit the drug for regulatory approval by the end of the year and aims for a global launch. Eli Lilly and Company (NYSE:LLY) is an international pharmaceutical company that discovers, develops, and markets medicines across various health areas. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

SK hynix Sees HBM Growing 30% Annually
SK hynix Sees HBM Growing 30% Annually

Yahoo

time3 minutes ago

  • Yahoo

SK hynix Sees HBM Growing 30% Annually

SK hynix (HXSCF) says demand for high bandwidth memory (NYSE:HBM) used in AI can grow about 30% a year through 2030, leaning on what it calls firm end user appetite and rising cloud capex. In an interview with Reuters, Choi Joon yong, who oversees HBM business planning, put it plainly: AI demand from the end user is pretty much very firm and strong. He added that spending by Amazon (NASDAQ:AMZN), Microsoft (NASDAQ:MSFT) and Google (NASDAQ:GOOG) will likely be revised higher, which would be positive for HBM. SK hynix expects the custom HBM market to reach tens of billions of dollars by 2030. Warning! GuruFocus has detected 3 Warning Sign with AMZN. That upbeat view plays down worries that higher pricing could cool orders in a segment long treated like a commodity. The company is betting AI accelerators keep pulling HBM into both training and inference, supporting volume, mix and long term visibility. A 30% growth path signals durable demand and potential pricing power for leading AI memory suppliers. Moreover, SK hynix sees a long runway for HBM, and investors will watch 2025 capex updates from AMZN, MSFT, and GOOG for confirmation. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cantor Fitzgerald Maintains Neutral Rating on Polestar (PSNY) Despite Delivery Beat
Cantor Fitzgerald Maintains Neutral Rating on Polestar (PSNY) Despite Delivery Beat

Yahoo

time3 minutes ago

  • Yahoo

Cantor Fitzgerald Maintains Neutral Rating on Polestar (PSNY) Despite Delivery Beat

Polestar Automotive Holding UK PLC (NASDAQ:PSNY) is one of the best EV penny stocks to buy according to hedge funds. On July 14, Cantor Fitzgerald reaffirmed its 'Neutral' rating on Polestar shares, despite the company reporting second-quarter 2025 delivery results that exceeded estimates. Polestar delivered 18,049 vehicles in the quarter, beating Cantor Fitzgerald's estimate of 11,744 vehicles and up from 13,072 deliveries in Q2 2024. The company delivered 30,319 cars in the first half of 2025, a 51% increase compared to the same period in 2024. Despite the strong delivery numbers, Cantor Fitzgerald cited Polestar's decision to pause its 2025 financial guidance (as of May 12, 2025) due to deteriorating macroeconomic conditions and uncertainty about tariffs as a reason for maintaining a 'Neutral' outlook. The analysts highlighted continuing risks, including significant capital requirements, 'Material impacts from tariffs and geopolitical tensions' due to Polestar's main manufacturing base in China, a substantial debt burden of $5.12 billion, and a negative gross profit margin of -43%. Polestar Automotive Holding UK PLC (NASDAQ:PSNY) is a Swedish EV manufacturer. The company designs and sells premium battery-electric cars, including the Polestar 2 fastback sedan, the Polestar 3 and 4 SUVs, and the upcoming Polestar 5 grand tourer. Polestar also offers performance software upgrades, carbon credits, and vehicle leasing services. While we acknowledge the potential of PSNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Performing Crypto Stocks So Far in 2025 and 10 Best Low-Risk Index Funds to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store